Skip to main content

Prudential Begins Genomics Coverage; Myriad Takes a Beating

NEW YORK, Feb. 21 - Prudential Securities on Thursday said that it has begun covering Celera Genomics, Human Genome Sciences, Millennium Pharmaceuticals, Myriad Genetics, and Tularik.


Analyst Christopher Raymond set the following price targets: Celera, $33; HGS, $28; Millennium, $38; Myriad, $25; and Tularik, $22, according to Reuters.

 

The analyst rated Myriad a 'sell,' Celera and Millennium a 'buy,' and HGS and Tularik a 'hold.' He said that Myriad presents "significant commercial, collaborative and commercial risk" in the near term, and that its genetic tests will fall flat among investors.


The market quickly responded: Myriad shares fell $3.84, or close to 10 percent, to $35.15 in mid-afternoon trading. Millennium inched up $.38 to $20.46, Celera jumped 60 cents to $21.34, Tularik dipped $.38 to $18.81, and HGS gained $.59 to sell at $24.62. All companies trade on the Nasdaq.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.